Replimune (NASDAQ: REPL) reported 3-year landmark overall survival data from the IGNYTE trial of RP1 plus nivolumab in anti–PD-1–failed advanced melanoma at the 2026 ASCO meeting.

Median overall survival reached 32.9 months; 3-year overall survival was 47.8% for all treated patients and 83.5% for responders. Objective response rate was 33.6% with a median duration of response of 24.8 months, and 44.8% of responders maintained responses at 3 years. A survival benefit was seen across key subgroups, with a predominantly Grade 1–2 safety profile and no Grade 5 events reported.